Revenue: As of FY2026 Q1, the actual value is USD 43.06 M.

EPS: As of FY2026 Q1, the actual value is USD 0.11.

EBIT: As of FY2026 Q1, the actual value is USD 17.71 M.

Financial Performance Highlights (Three Months Ended March 31, 2026)

Operational Metrics

• Net Income Attributable to SBC Medical Group Holdings Incorporated: $11,308,071, representing a 47% year-over-year decrease .
• Net Income Margin: 26% for the first quarter of 2026, a year-over-year decrease of 19 percentage points from 45% in 2025 .
• Gross Profit: $30,346,734, compared to $37,733,084 for the same period in 2025 .
• Selling, General and Administrative Expenses: $12,626,719, compared to $13,531,010 for the same period in 2025 .
• Income from Operations: $17,720,015, compared to $24,202,074 for the same period in 2025 .
• EBITDA: $18,390,449, marking a 26% year-over-year decrease .
• EBITDA Margin: 43% for the first quarter of 2026, a year-over-year decrease of 10 percentage points from 52% in 2025 .
• Return on Equity: 18%, representing a 23 percentage point year-over-year decrease .

Cash Flow

• Net Cash Provided by Operating Activities: $9,231,938, significantly up from $1,928,621 in the prior year period .
• Free Cash Flow: Not explicitly provided or directly calculable from the given financial statements within the reference .

Balance Sheet Snapshot (as of March 31, 2026)

• Cash and Cash Equivalents: $167,305,095, an increase from $163,773,838 as of December 31, 2025 .
• Total Liabilities: $117,635,399, compared to $117,143,240 as of December 31, 2025 .
• Total Stockholders’ Equity: $270,384,177, compared to $263,304,706 as of December 31, 2025 .

Unique Operational Metrics

• Number of Franchise Locations: 284 as of March 31, 2026, an increase of 33 locations from March 31, 2025 .
• Number of Customers: 6.76 million in the last twelve months ended March 31, 2026, a 10% year-over-year increase .
• Repeat Rate for Customers: 72% for customers who visited franchisee’s clinics twice or more .

Outlook / Guidance

SBC Medical Group Holdings Incorporated plans to continue its multi-brand strategy in aesthetic dermatology and expand its non-aesthetic medical business, while also strengthening its operational foundation in overseas markets . The company will pursue opportunities in the longevity market and enhance services through AI, aiming to build a sustainable and continuously growing healthcare platform .